Tinyteddy, I think your post is correct on all points - thanks for painting the picture so clearly on the clinical efficacy issue. It is why we are appealing the TGA decision not to approve Nasodine on the existing data.
JamesQuinn, thanks for the feedback; we will always try to be as transparent and complete as possible so that investors can make a clear assessment of the risks and the value proposition. I can't comment on the price, but I do like your suggestion
FRE Price at posting:
23.0¢ Sentiment: None Disclosure: Held
